|
Jun 26
|
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
|
|
Jun 25
|
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET
|
|
Jun 25
|
Sector Update: Health Care Stocks Advance Late Afternoon
|
|
Jun 25
|
Top Midday Gainers
|
|
Jun 25
|
Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer
|
|
Jun 24
|
Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing
|
|
Jun 19
|
Plus (PSTV) Upgraded to Buy: Here's Why
|
|
May 23
|
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q
|
|
Apr 24
|
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics
|
|
Apr 23
|
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
|
|
Apr 23
|
Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors
|
|
Mar 21
|
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug
|
|
Mar 21
|
Why Plus Therapeutics Inc. (PSTV) Surged On Thursday?
|
|
Mar 20
|
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
|
|
Sep 4
|
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
|
Jul 25
|
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference
|
|
Mar 27
|
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
|
|
Mar 25
|
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
|
|
Dec 18
|
Plus Updates Financial and Cash Guidance for 2024
|
|
Nov 29
|
Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe
|